Physician profile
Ajit Kokkat
NPI 1962438143
$10,541.25
in general payments reported to CMS, 2019-2025
37 companies · $1,714 in 2025
The $1,714 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,474 · 2020: $1,363 · 2021: $1,497 · 2022: $1,739 · 2023: $1,449 · 2024: $1,305 · 2025: $1,714.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,458 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,458.20 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,345.37 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,543.89 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,274.40 | 2019-2024 | Trulance, Xifaxan |
| Ironwood Pharmaceuticals, INC | $643.35 | 2019-2024 | Linzess |
| Celgene Corporation | $599.11 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $517.73 | 2022-2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $441.69 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $403.75 | 2019-2025 | Tremfya, Stelara, Simponi |
| Nestle Healthcare Nutrition INC. | $400.08 | 2020-2023 | |
| Gilead Sciences, INC. | $306.78 | 2019-2025 | |
| Madrigal Pharmaceuticals | $258.02 | 2025 | Rezdiffra |
| Pfizer INC. | $252.62 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $215.71 | 2019-2023 | Rebyota |
| Redhill Biopharma INC. | $175.45 | 2020-2023 | Talicia |
| Qol Medical, LLC | $157.47 | 2019-2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $141.23 | 2024-2025 | Omvoh |
| Ethicon US, LLC | $124.31 | 2019-2022 | |
| Aimmune Therapeutics, INC. | $103.19 | 2025 | Zenpep |
| Allergan, INC. | $91.99 | 2019-2020 | |
| Alfasigma USA, INC. | $91.38 | 2020-2021 | |
| Daiichi Sankyo INC. | $60.08 | 2023 | Injectafer |
| Boston Scientific Corporation | $59.31 | 2021-2025 | Resolution 360 Clip |
| Merck Sharp & Dohme LLC | $55.33 | 2021-2025 | Bridion |
| Regeneron Healthcare Solutions, INC. | $48.90 | 2022-2023 | Dupixent |
| Amgen INC. | $31.38 | 2025 | |
| Vivus LLC | $22.99 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $22.85 | 2025 | Iqirvo |
| Alnylam Pharmaceuticals INC. | $22.45 | 2021 | |
| Stryker Corporation | $21.32 | 2019 | |
| Shionogi INC | $20.24 | 2020 | |
| Braintree Laboratories, INC. | $15.68 | 2019 | |
| Shire North American Group INC | $15.05 | 2019 | |
| Sandoz INC. | $14.96 | 2023 | Hyrimoz |
| Ucb, INC. | $14.47 | 2020 | |
| Intercept Pharmaceuticals, INC. | $14.37 | 2020 | |
| Evoke Pharma, INC. | $14.35 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajit Kokkat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.